The partnership will be called “Accelerating COVID-19 Therapeutic Interventions and Vaccines,” or ACTIV, and is intended to standardize research between federally funded researchers and the drug companies. The organization will prioritize research into drugs and vaccines that have high near-term potential, the NIH said.
ACTIV will give researchers access to high-level lab facilities, ensure researchers are judging potential drugs by the same criteria and establish a system to precisely coordinate clinical trials, according to STAT.
The 16 drug companies involved in ACTIV are: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Evotec, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda and Vir Biotechnology.
Read the full news release here.
More articles on pharmacy:
DEA lifts 3 restrictions on hospitals, pharmacies during COVID-19 pandemic
Relief fund started for pharmacy employees affected by COVID-19
Walmart accused of hiding criminal investigation by plaintiffs in federal opioid case
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.